ProKidney Corp. Class A Ordinary Shares (PROK)

Price$1.80

Value ScoreF

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-26.84%

Price vs S&P 500 (4W)-3.22%

VGM Score40.20

Market Capitalization$543.71M

All Metrics

Book Value / Share (Quarterly)$0.11

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.50

Price vs S&P 500 (YTD)-27.80%

Net Profit Margin (TTM)-8131.50%

EPS (TTM)$-0.53

10-Day Avg Trading Volume1.17M

EPS Excl Extra (TTM)$-0.53

EPS (Annual)$-0.52

ROI (Annual)-204.26%

Cash / Share (Quarterly)$0.74

Revenue Growth QoQ (YoY)-1.74%

ROA (Last FY)-20.56%

Revenue Growth TTM (YoY)190.52%

EBITD / Share (TTM)$-1.18

Operating Margin (TTM)-18959.73%

Cash Flow / Share (Annual)$-0.45

P/B Ratio82.38x

P/B Ratio (Quarterly)322.02x

Net Income / Employee (Annual)$-298,600

EV / Revenue (TTM)497.06x

ROA (TTM)-21.39%

EPS Incl Extra (Annual)$-0.52

Current Ratio (Annual)9.13x

Quick Ratio (Quarterly)8.78x

3-Month Avg Trading Volume0.90M

52-Week Price Return128.72%

Revenue / Employee (TTM)$3,800

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)608.85x

Asset Turnover (Annual)0.00x

52-Week High$7.13

EPS Excl Extra (Annual)$-0.52

CapEx CAGR (5Y)22.72%

26-Week Price Return-18.92%

Quick Ratio (Annual)8.91x

13-Week Price Return-23.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.06x

Enterprise Value$441.88M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$3,900

Pretax Margin (Annual)-16931.47%

Cash / Share (Annual)$0.90

3-Month Return Std Dev70.14%

Net Income / Employee (TTM)$-312,900

ROE (Last FY)-205.02%

EPS Basic Excl Extra (Annual)$-0.52

Total Debt / Equity (Quarterly)5.40x

EPS Incl Extra (TTM)$-0.53

P/S Ratio (TTM)611.59x

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$-17.82

Price vs S&P 500 (52W)104.35%

Year-to-Date Return-19.64%

5-Day Price Return-2.70%

EPS Normalized (Annual)$-0.52

ROA (5Y Avg)-40.11%

Net Profit Margin (Annual)-7725.20%

Month-to-Date Return-1.64%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-1.18

Operating Margin (Annual)-18477.83%

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)337.35x

Pretax Margin (TTM)-17599.33%

Book Value / Share (Annual)$-17.82

Price vs S&P 500 (13W)-31.66%

Beta1.79x

Revenue / Share (TTM)$0.01

ROE (TTM)-28.10%

52-Week Low$0.54

vGradeF

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.14est. -0.14

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.93

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
PROKProKidney Corp. Class A Ordinary Shares	F	B	C	$1.80
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

ProKidney Corp is a clinical-stage biotechnology company developing REACT, a patient-derived cell therapy designed to slow and stabilize the progression of chronic kidney diseases. The proprietary platform uses autologous renal cells to create personalized, disease-modifying treatments addressing a significant unmet medical need. The company's development pipeline is currently focused on severe diabetic kidney disease.